Physician profile
Tyler Kang
NPI 1164691820
$13,968.30
in general payments reported to CMS, 2019-2025
77 companies · $4,963 in 2025
The $4,963 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,433 · 2020: $301 · 2021: $933 · 2022: $497 · 2023: $423 · 2024: $4,419 · 2025: $4,963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,433 · Education: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,433.08 |
| Education | $372.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,103.44 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $939.24 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $910.95 | 2019-2025 | Tagrisso, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $853.22 | 2019-2025 | |
| Pfizer INC. | $834.35 | 2019-2025 | |
| Janssen Biotech, INC. | $817.86 | 2019-2025 | Erleada, Akeega, Darzalex |
| Celgene Corporation | $696.97 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $601.56 | 2019-2025 | Iclusig, Ninlaro, Fruzaqla |
| Daiichi Sankyo INC. | $598.57 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Genentech USA, INC. | $435.83 | 2019-2025 | Polivy, Phesgo, Itovebi |
| Array Biopharma INC | $411.27 | 2019-2025 | Mektovi, Braftovi, Tukysa |
| Lilly USA, LLC | $395.79 | 2019-2025 | Verzenio, Jaypirca |
| Seagen INC. | $322.31 | 2019-2025 | |
| Astellas Pharma US INC | $320.17 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Abbvie INC. | $307.97 | 2024-2025 |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $209.47 | 2019-2025 | Trodelvy |
| Eisai INC. | $200.35 | 2019-2025 | |
| Genzyme Corporation | $200.22 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $196.70 | 2019-2025 | |
| Glaxosmithkline, LLC. | $192.89 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Myriad Genetic Laboratories, INC. | $163.78 | 2022-2025 | Precisetumor, Myrisk |
| Amgen INC. | $160.09 | 2019-2025 | Evenity |
| Puma Biotechnology, INC. | $151.07 | 2021-2024 | |
| Novocure INC. | $144.90 | 2019-2025 | Optune Lua (Novottf-200t) |
| Alexion Pharmaceuticals, INC. | $122.68 | 2019-2025 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $118.85 | 2019-2025 | Libtayo |
| Incyte Corporation | $118.82 | 2024-2025 | Monjuvi, Jakafi, Zynyz |
| Exelixis INC. | $118.01 | 2025 | Cabometyx |
| Adc Therapeutics America, INC. | $113.64 | 2024-2025 | |
| Beone Medicines USA, INC. | $110.07 | 2025 | Tevimbra, Brukinsa |
| Amag Pharmaceuticals, INC. | $103.08 | 2020 | |
| Genmab U.S., INC. | $97.89 | 2024-2025 | Epkinly |
| Karyopharm Therapeutics INC. | $88.90 | 2024-2025 | Xpovio |
| Coherus Oncology, INC. | $87.72 | 2024 | |
| Silk Road Medical, INC. | $79.58 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Aveo Pharmaceuticals, INC. | $76.08 | 2025 | |
| Medtronic, INC. | $73.32 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $70.14 | 2019-2021 | |
| Syndax Pharmaceuticals, INC. | $68.68 | 2025 | |
| Springworks Therapeutics, INC. | $68.68 | 2024-2025 | Ogsiveo |
| Ipsen Biopharmaceuticals, INC | $66.16 | 2024-2025 | Onivyde |
| Deciphera Pharmaceuticals INC. | $64.17 | 2025 | Romvimza, Qinlock |
| Kyowa Kirin, INC. | $64.10 | 2022-2024 | Poteligeo |
| Jazz Pharmaceuticals INC. | $61.75 | 2024-2025 | |
| Kite Pharma, INC. | $61.44 | 2020-2025 | Yescarta |
| Beigene USA, INC. | $58.63 | 2025 | Tevimbra, Brukinsa |
| Foundation Medicine, INC. | $56.89 | 2019-2023 | |
| Sobi, INC | $56.43 | 2025 | |
| Geron Corporation | $50.71 | 2025 | Rytelo |
| Pharmaessentia USA Corporation | $44.41 | 2024-2025 | Besremi |
| Spectrum Pharmaceuticals INC. | $43.25 | 2024-2025 | Rolvedon |
| Acrotech Biopharma INC. | $39.83 | 2022 | |
| Taiho Oncology, INC. | $38.44 | 2019-2024 | |
| Iovance Biotherapeutics, INC. | $34.95 | 2025 | Amtagvi |
| Dendreon Pharmaceuticals LLC | $33.97 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.70 | 2019-2025 | |
| Genentech, INC. | $32.96 | 2024 | Lunsumio, Columvi |
| Pharmacosmos Therapeutics INC. | $32.50 | 2025 | Monoferric |
| Biocon Biologics INC | $32.23 | 2024 | Fulphila |
| Lexicon Pharmaceuticals, INC. | $31.01 | 2019 | |
| Caris Mpi, INC. | $28.37 | 2025 | Mi Cancer Seek |
| Apo-Pharma USA, INC. | $27.47 | 2019 | |
| Myovant Sciences INC. | $25.42 | 2021 | |
| Tersera Therapeutics LLC | $24.39 | 2025 | Zoladex |
| Biocompatibles, INC. | $22.88 | 2019 | |
| Mirati Therapeutics, INC. | $22.40 | 2024 | Krazati |
| Sumitomo Pharma America, INC. | $21.24 | 2024 | Orgovyx |
| Progenics Pharmaceuticals, INC. | $20.04 | 2025 | |
| Napo Pharmaceuticals INC | $19.95 | 2025 | Gelclair Concentrated Oral Gel |
| Azurity Pharmaceuticals, INC. | $18.85 | 2024 | Vivimusta |
| Boston Scientific Corporation | $18.01 | 2020 | |
| Smith+Nephew, INC. | $17.56 | 2021 | |
| Immunogen, INC. | $16.50 | 2023 | Elahere |
| Teleflex LLC | $16.24 | 2021 | |
| Advanced Accelerator Applications | $16.10 | 2019 | |
| Recordati_rare_diseases_inc. | $15.49 | 2025 | Sylvant |
| Bard Peripheral Vascular, INC. | $14.75 | 2022 |
Drugs and devices associated with these payments
Keytruda $878Opdivo $712Enhertu $412Erleada $366Reblozyl $340Tukysa $333Epkinly $330Braftovi $310Mektovi $310Adcetris $306Elrexfio $279Lynparza $270Imbruvica $262Iclusig $205Tagrisso $204Xtandi $201Akeega $194Kisqali $163Enroute Transcarotid Neuroprotection System $159Bosulif $142Ninlaro $140Lenvima $137Darzalex $135Verzenio $133Nubeqa $133Welireg $128Calquence $122Tevimbra $121Jemperli $120Zejula $120Ibrance $119Cabometyx $118Polivy $116Jaypirca $106Precisetumor $106Ultomiris $101Scemblix $98.84Rybrevant $90.12Libtayo $89.74Xpovio $88.90Lutathera $87.77Opdualag $85.71Fabhalta $85.49Xofigo $84.77Pluvicto $84.29Sarclisa $81.27Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter $79.58Enroute Transcarotid Stent $79.58Phesgo $76.90Fotivda $76.08Monjuvi $73.63Imfinzi $73.31Ojjaara $73.16Lunsumio $71.35Ogsiveo $68.68Onivyde $66.16Vyloy $65.22Lorbrena $64.56Romvimza $64.17Qinlock $64.17Trodelvy $62.33Udenyca $57.15Orgovyx $55.73Talzenna $55.11Balversa $52.42Itovebi $52.15Poteligeo $51.89Pomalyst $51.32Rytelo $50.71Vitrakvi $48.16Stivarga $48.16Brukinsa $47.39Optune Lua (Novottf-200t) $45.82Fruzaqla $45.56Jakafi $45.19Besremi $44.41Datroway $43.42Rolvedon $43.25Yescarta $42.92Myrisk $42.33Tivdak $39.23Amtagvi $34.95Oxbryta $34.87Ziihera $34.48Zynlonta $33.12Columvi $32.96Monoferric $32.50Fulphila $32.23Xalkori $32.02Loqtorzi $30.57Keytruda Qlex $29.04Vonjo $28.69Mi Cancer Seek $28.37Doptelet $27.74Zepzelca $27.27Breyanzi $27.27Padcev $26.95Zynyz $26.66Venclexta $26.12Kadcyla $26.10
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.